---
title: BRAFV600E induces key features of LCH in iPSCs with cell type-specific phenotypes
  and drug responses
date: '2024-12-04'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39630039/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20241204174910&v=2.18.0.post9+e462414
source: Blood
description: Langerhans cell histiocytosis (LCH) is a clonal hematopoietic disorder
  defined by tumorous lesions containing CD1a+/CD207+ cells. Two severe complications
  of LCH are systemic hyperinflammation and progressive neurodegeneration. The scarcity
  of primary samples and lack of appropriate models limit our mechanistic understanding
  of LCH pathogenesis and affect patient care. We generated a human in vitro model
  for LCH using induced pluripotent stem cells (iPSCs) harboring the BRAFV600E mutation,
  ...
disable_comments: true
---
Langerhans cell histiocytosis (LCH) is a clonal hematopoietic disorder defined by tumorous lesions containing CD1a+/CD207+ cells. Two severe complications of LCH are systemic hyperinflammation and progressive neurodegeneration. The scarcity of primary samples and lack of appropriate models limit our mechanistic understanding of LCH pathogenesis and affect patient care. We generated a human in vitro model for LCH using induced pluripotent stem cells (iPSCs) harboring the BRAFV600E mutation, ...